All
P&G researchers sequence genome of dandruff-causing fungus
December 4th 2007Cincinnati - Reuters reports that researchers at Procter & Gamble say they have sequenced the genome of Malassezia globosa, a fungus that grows on the skin of between 50 percent and 90 percent of the population, causing dandruff and other skin conditions.
Clinical trial to evaluate efficacy of Isolagen Therapy for treating acne scars
December 4th 2007Exton, Pa. - Biotech company Isolagen, based here, has announced the initiation of a phase 3 clinical study to test Isolagen Therapy for the treatment of moderate to severe acne scars, PRNewswire reports.
Study shows effectiveness of golimumab in treating psoriatic arthritis
December 4th 2007Boston - Results of what is reportedly the largest phase 3 study ever conducted with a biologic treatment suggest that patients with active psoriatic arthritis (PsA) achieve significant, sustained improvements in joint and skin manifestations of the disease after monthly subcutaneous injections of investigative golimumab, DocGuide.com reports.
NIH awards grant to Cleveland institutions for psoriasis research
December 4th 2007Cleveland - The Case Western Reserve University medical school and University Hospitals Case Medical Center have received a five-year, $6.37 million grant from the National Institutes of Health to find new treatments for psoriasis, Crain’s Cleveland Business reports.
Doctor objects to AAD logo appearing on sun protection products
December 1st 2007The American Academy of Dermatology announced in May 2007 that it had launched its Seal of Recognition program, in which the Academy charges companies thousands of dollars for the right to display the Academy's logo on sun protection products that meet the Academy's criteria. Academy members who back the program say it is a noble cause that will greatly fuel the organization's skin cancer education efforts.
Can studies funded by manufacturers yield valid, objective results?
December 1st 2007With the decreases in government funding of medical trials, manufacturers of the products being tested finance more and more clinical trials, whether for medication, therapies or equipment. Tests are obviously needed to determine the effectiveness and safety of new products in order to make medical progress. That system, however, can put unpredictable pressure on physicians conducting the trials.
Your Web site: Do you need the bells and whistles?
December 1st 2007Websites range from those structured as online brochures to the more complicated interactive sites. Whether you need the bells and whistles of interaction depends on your goals, how much you want to spend and how much effort you plan to focus on the web.
Senators ponder ethical conflicts of doctor-drug company relationships
December 1st 2007Congress has been warned that many doctors are "on the take" from big pharmaceutical companies, which pay them in one way or another to prescribe their drugs to patients, and are "at risk of corruption" while endangering the lives of patients.
Defining terms: Dysyplastic debate continues
December 1st 2007In the Letters section of the October 2007 issue of Dermatology Times, both Craig G. Burkhart, M.D., and Michael H. Coverman, M.D., do not directly address two important points in the debate regarding "dysplastic" nevi. Clinical utility of a concept derives from its prognostic and therapeutic implications. Specifically, the utility of the concept of dysplastic nevi is that they are a significant risk factor for cutaneous melanoma.[1,2] This concept is analogous to hypercholesterolemia and hypertension being asymptomatic risk factors for cardiovascular disease and not diseases in and of themselves.